Is NCT06132035 recruiting in Erie, PA?

Yes, NCT06132035 is currently recruiting participants at its Erie, PA location. This age-related wet macular degeneration clinical trial is actively enrolling qualified participants.

How do I join the age-related wet macular degeneration clinical trial in Erie?

To join this clinical trial in Erie, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Erie clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Age-related Wet Macular Degeneration Clinical Trial in Erie, PA

Who Can Participate

Inclusion Criteria

Male or female patients ≥50 years of age

Willing and able to provide written informed consent

Diagnosis of age-related wet macular degeneration (wAMD) in the study eye as determined by the investigator on fundus examination

Primary or recurrent active choroidal neovascularization (CNV) lesions involving the foveal center secondary to age-related wet macular degeneration in any one of the eyes. (If both eyes are affected and eligible, the eye with the worse BCVA, as assessed at screening, will be selected as the study eye

Best corrected visual acuity (BCVA) of 75-25 eye Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (approximate Snellen equivalent between 20/ 32 to 20/320) inclusive before pupil dilation assessed at the initial testing distance of 4 meters

Central Subfield Thickness (CST thickness) ≥ 250 microns on SD-OCT (exclusive of subretinal pigment epithelial fluid, inclusive of SRF)

Presence of SRF and/or IRF on SD-OCT

Total lesion size not greater than 12 disc areas (30.48 mm2) (1 disc area = 2.54 mm2) on FA

If present, subretinal hemorrhage must comprise \< 50% of the total lesion area on FA, SD-OCT, or FAF

No subfoveal fibrosis or atrophy on FA, SD-OCT, or FAF

Active CNV membranes with subfoveal leakage or juxtafoveal leakage too close for laser photocoagulation

Females who are of non-childbearing potential (surgically sterile or menopausal) OR if of childbearing potential using effective birth control and non-pregnant \& non-lactating

Ability to follow protocol requirements

Exclusion Criteria

Patients having additional eye disease in the posterior segment of study eye other than wAMD

Any other pathology involving the CNV lesion like retro foveolar atrophy or permanent structural damage to fovea or fibrosis/ hemorrhage involving fovea \> 50 % of lesion area of study eye that can affect the efficacy of drug

Vitreous hemorrhage or history of rhegmatogenous retinal detachment, retinal pigment epithelial tear involving the macula or macular hole (stage 3 or 4) in the study eye

Aphakia or absence of the posterior capsule in the study eye

History or expectation of the following surgery in the study eye:

Vitrectomy within last 1 month

Cataract surgery or Lasik within the last 3 months

Planned cataract removal surgery during the study

A history or medical diagnosis of uncontrolled glaucoma (defined as IOP \>25mmHg even with anti-glaucoma medication), advanced glaucoma resulting in a cup/disc ratio \>0.8 in the study eye, or glaucoma filtration surgery in the study eye

Serious complications following surgery in the study eye within 1 year

Current or planned use of medications known to be toxic to the retina, lens, or optic nerve (e.g., deferoxamine, chloroquine/hydro chloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol)

Medical history or condition: Uncontrolled diabetes mellitus, with glycosylated hemoglobin (HbA1c) \> 10%, myocardial infarction or stroke within 12 months of screening, active bleeding disorder, major surgery within 1 month of screening or when planned within the study period, hepatic impairment, uncontrolled hypertension, other unstable or progressive cardiovascular, pulmonary, Parkinson, liver, or renal disease or cancer or dementia

Previous treatment with intravenous bevacizumab or intravitreal ranibizumab, bevacizumab, aflibercept, pegaptanib in either of the eyes within four months prior to enrolment

Previous treatment with verteporfin photodynamic therapy (PDT), thermal laser, transpupillary thermotherapy, intravitreal or protein kinase C inhibitors or other AMD therapy in the study eye within 3 months prior to randomization

Previous treatment with intravitreal ocular or periocular steroids (e.g., triamcinolone, anecortave acetate) or peribulbar steroid in the study eye within past 3 months

Concurrent use of systemic anti-VEGF agents

Any ophthalmic device implantation within the previous 12 months

Patients with a clinically significant abnormal screening hematology, blood chemistry, or urinalysis, unsuitable for study participation in the investigator's opinion

Aspartate Transaminase (AST), Alanine Transaminase (ALT), alkaline phosphatase, Gamma-glutamyl Transferase (GGT), total bilirubin, direct bilirubin, indirect bilirubin, and LDH ≥ 2.0-fold the upper limit of normal at screening

Patient with impaired renal function defined as calculated creatinine clearance (CLCr) \<30mL/min

Males: CLCr = \[140 - a(years)\] x weight(kg)/ 72 x serum creatinine (mg/dL)

Females: CLCr = \[140 - a(years)\] x weight(kg) (x 0.85)/ 72 x serum creatinine (mg/dL)

Significant alcohol or drug abuse within past 2 years per investigator judgement

Previous participation in other trials for treatment of wAMD with systemic administration if washout period from last administration is shorter than 3 months

Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in the any of the following:

Put the patient at risk because of participation in the study,

Influence the results of the study,

Cause concern regarding the patient's ability to participate in the study

Known hypersensitivity to fluorescein or any of the ingredients used in the study drug formulation, or any of the medications used during the study

Active infectious conjunctivitis in either eye

Women of childbearing potential who are lactating or who are pregnant as determined by serum pregnancy test at screening

Women of childbearing potential must have agreed to use adequate birth control methods for the duration of the study

Post-menopausal women should have documented last MC 2 years before study participation

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Erie?

Yes, this clinical trial (NCT06132035) has an active research site in Erie, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Age-related Wet Macular Degeneration Treatment Options in Erie, PA

If you're searching for age-related wet macular degeneration treatment options in Erie, PA, this clinical trial (NCT06132035) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Erie research site is actively enrolling participants for this clinical trial. You'll receive care from experienced age-related wet macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all age-related wet macular degeneration clinical trials near you to find additional studies recruiting in your area.

Age-related Wet Macular Degeneration Clinical Trial in Erie, PA

Expert Care in Erie

IRB Approved

No-Cost Care

Apply for This Erie Location

Why Participate?

Simple Process

About This Age-related Wet Macular Degeneration Study in Erie